The raised FFO as Adjusted and Same-Store NOI guidance, combined with strong senior housing same-store NOI growth of 25.9%, signal improving operational momentum. Monitor the closing of the four life science building acquisitions and the integration of Janus Living's $1.75B of senior housing acquisitions for further upside.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $19.56entry
- T+1 · 13d ago +3.12%α +1.47% · $20.17
- T+5 · 7d ago +4.35%α +4.93% · $20.41
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Healthpeak Properties reported Q3 2026 FFO as Adjusted of $0.44 per share, in line with the $0.43 consensus, and total revenue of $820.9M, above the $743.5M consensus. The company raised its full-year 2026 FFO as Adjusted guidance to $1.76-$1.78 per share (from $1.73-$1.77) and its Same-Store Cash NOI growth guidance to 0.5%-2.0% (from 0%-1.5%). Total same-store Adjusted NOI grew 3.6% year-over-year, driven by 25.9% growth in senior housing, partially offset by a 0.7% decline in lab.
Key Financial Metrics
Key Facts
- Diluted FFO as Adjusted per share of $0.44 for Q3 2026, compared to $0.46 in Q3 2025
- Total revenue of $820.9M, up 16.3% from $705.9M in Q3 2025
- Full-year 2026 FFO as Adjusted guidance raised to $1.76-$1.78 per share from $1.73-$1.77
- Full-year 2026 Same-Store Cash NOI growth guidance raised to 0.5%-2.0% from 0%-1.5%
- Total same-store Adjusted NOI grew 3.6% year-over-year
- Senior Housing same-store Adjusted NOI grew 25.9% year-over-year
- Lab same-store Adjusted NOI declined 0.7% year-over-year
- Net Debt to Adjusted EBITDAre was 4.7x for the quarter
- Acquired or under contract to acquire four life science buildings for approximately $233 million
- Entered into a new $500 million unsecured delayed-draw term loan facility
Financial Impact
FFO as Adjusted guidance raised by $0.02 per share at the midpoint; Same-Store NOI guidance raised by 50 bps at the midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Outpatient Medical | $314.8M | -3.6% |
| Lab | $223.9M | +4.9% |
| Senior Housing | $268.3M | +78.3% |
Risk Factors
- Lab same-store Adjusted NOI declined 0.7% year-over-year, indicating continued weakness in the life science segment
- GAAP EPS guidance was lowered to $0.39-$0.41 from $0.48-$0.52 due to increased depreciation from Janus Living acquisitions
- AFFO capital expenditures increased to $37.6M in Q3 2026 from $27.3M in Q3 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-068878 |
| Exhibit: ex99109302026.htm | 0001628280-26-068878 |
| Document: peak-20261102.htm | 0001628280-26-068878 |
| Document: 0001628280-26-068878-index-headers.html | 0001628280-26-068878 |
| Document: 0001628280-26-068878-index.html | 0001628280-26-068878 |
| Document: 0001628280-26-068878.txt | 0001628280-26-068878 |
| 8-K Data (Synthetic) | 0001628280-26-068878 |
Track record
4 reports on DOC
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $20.41 Now $19.84 −2.79% settles Nov 17
- Nov 2, 202614d ago 8-K Bullish 5/10 Viewing Entry $19.56 to $20.41 Now $19.84 +1.43% ▲ +4.35% +4.93% vs SPY
- Oct 20, 202627d ago Institutional Cluster Mixed 3/10 Entry $18.48 to $19.02 Now $19.84 +7.36% ▲ +2.92% +3.37% vs SPY
- Feb 27, 202637w ago 8-K Neutral 3/10 Entry $17.47 to $17.08 Now $19.84 +13.55% ▼ −2.26% −0.28% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers